查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198082

临床前成像市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Preclinical Imaging Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内（2022 年至 2027 年），临床前成像市场预计将以近 6.00% 的复合年增长率增长。

当前 2019 冠状病毒病 (COVID-19) 危机正在加深，临床实践正在发生重大变化。 根据 2020 年发表的论文“当前的冠状病毒病 2019 (COVID-19) 危机持续增长并导致临床操作发生显着变化”，学术医疗机构和大学在临床准备的同时，我们已经紧急停止了科学研究活动，以最大限度地保持社交距离，并最大限度地减少感染对研究人员和潜在接触者的传播。 放射学领域的研究人员一直在努力解决这些继续影响当前和未来成像研究的问题。

但是，由于旅行限制和改进的健康预防措施，一些製造商已经恢復运营。 例如，Euro-BioImaging Node 现在根据 COVID-19 设置为外部用户提供服务。 此外，Euro-BioImaging 通过图像数据交换支持与 COVID-19 相关的研究活动，例如大型药物筛选项目。 该公司与协作研究基础设施 EU-OPENSCREEN 合作。 EU-OPENSCREEN 使用人体细胞和 SARS-CoV-2 分离株测试了 5,632 种化学物质抑制病毒引起的细胞毒性的能力，以确定针对 SARS-CoV-2 的临床试验候选物。 预计这将增加 COVID-19 大流行期间对临床前成像的需求。

2020 年 3 月，MILabs 还宣布了用于 COVID-19 动物模型体内成像的临床前诊断 U-CT，以便在预期抗病毒研究工具需求增加的情况下测试冠状病毒疫苗和药物。改进设备。 超高分辨率非侵入性肺部成像使研究人员能够精确定位小鼠、豚鼠和雪貂支气管中疾病过程的位置。 此外，对于与呼吸系统综合症相关的冠状病毒基因型的高通量筛选，可以使用本征低温框架肺部成像并同时扫描多达四个小鼠模型。

导致临床前成像市场增长的关键因素包括分子成像技术的进步、对非侵入性小动物成像技术的需求增加以及私人和公共机构对临床前研究的资金增加。

分子成像是一种快速发展的跨学科技术，包括分子生物学、化学、计算、工程学和医学。 分子成像能够在细胞或分子水平上对体内生理和病理过程进行非侵入性实时可视化和测量。

多模态分子影像增强了临床医生在筛查、监测、分期、预后预测、治疗计划与指导、疗效监测、復发评估等方面的能力，在多种疾病的临床治疗中具有重要的作用。

此外，多模态分子影像技术的使用具有实现预后检测、靶向治疗和个性化医疗的潜力，技术进步显着。 Aspect Imaging 与 Aspect 的 M2 平台和产品套件一起，使研究人员能够利用 MRI 的强大功能和定量洞察力进行小动物表型分析和药物开发，但成本和传统 MRI 系统的复杂性没有技术负担。

临床前成像市场趋势

微超声是医疗器械领域增长最快的市场

显微超声是超声波的微型化版本，有望有更广泛的应用，尤其是在小动物模型相关的研究中。 这种诊断成像技术的微型化版本增强了该技术的有效性。 根据 2020 年 5 月发表的题为“临床前超声成像 - 技术和成像应用综述”的研究，超声成像是一种临床工具，可提供实时和定量的人体解剖学和生理学信息。建立为一种图像技术。

此外，它还可以减少给定研究所需的动物数量。 在过去十年中，临床前成像已成为推进生物医学发现的重要工具。 高频微超声在后基因组时代稳步发展，成为一种快速且相对便宜的成像工具，用于研究使用小动物的正常发育和人类疾病模型。 这一发展的基本障碍之一是与高频阵列换能器相关的技术障碍。

产品发布也是市场增长的因素之一。 例如，2020 年 10 月，福克斯蔡斯癌症中心推出了一种新的显微超声系统，医生称该系统可能会改变前列腺癌的诊断和治疗方式。 预计此类批准将促进市场增长。

研究了临床前显微超声在发育生物学、癌症和心血管疾病中的应用。 未来还会有高频超声成像的最新进展。 在临床前研究中结合多种成像方式，使研究人员能够了解活体动物的分子、细胞和生理变化，并预测患者新疗法的结果。 因此，由于上述因素，预计市场在预测期内将出现高速增长。

临床前成像市场预计将由北美主导

由于其发达的基础设施、大量的临床前项目以及对先进技术设备的广泛采用，预计北美将主导临床前成像市场。

COVID-19 大流行及其后果对美国的学术研究产生了重大影响。 2019 年冠状病毒病 (COVID-19) 已经摧毁了世界，造成数亿人死亡、经济停摆、边境关闭并在全球范围内蔓延苦难。 由于距离和传播问题，大多数非 COVID 临床研究已停止。 当 SARS-CoV-2 在 2019 年底出现时，没有获得许可的药物或疫苗。 当前的传统药物研发模式从开始到结束需要数年时间，但在这场危机中迫切需要采取行动，因此受到了挑战。 抗病毒药、免疫调节剂和抗凝血剂等药物已经加速了可以作为“路线图”的途径，以帮助优先考虑用于临床试验的化合物。

因此，2020 年 4 月，美国国立卫生研究院 (NIH) 启动了加速宣布 COVID-19 治疗干预和疫苗 (ACTIV) 公私合作伙伴关係。

我们还知道，美国凭藉其完善的基础设施以及大型公共和私营公司的存在而主导着市场。 不断增加的研发资金加上高度发达的研究基础设施正在加速美国临床前成像市场的增长。

此外，越来越多的临床研究组织 (CRO) 和製药公司在临床前研究中越来越多地采用体内成像系统，进一步加速了该市场的增长。

此外，公司正在提供新产品以实现产品组合的多样化。 例如，2022 年 3 月，布鲁克宣布推出 Ultima Investigator Plus，这是其行业领先的 Ultima 系列多光子显微镜的更新模块化平台，用于深层组织荧光成像。 Investigator Plus 具有扩展的视野、优化的 2 光子和 3 光子成像光学器件以及增加的近距离耦合收集路径，使研究人员能够更深入地观察要求苛刻的标本。 此外，每家公司都在开发新产品以扩大其产品组合。 例如，布鲁克透露将于 2022 年 3 月推出 Ultima Investigator Plus。 它是行业领先的 Ultima 系列多光子显微镜用于深层组织荧光成像的最新灵活平台。 研究人员认为，扩大的视野、针对双光子和三光子成像优化的光学器件以及扩展的紧耦合收集路径将使科学家能够在标本内部深处成像并看到更多。

因此，所有这些因素都有助于该地区的市场增长。

临床前成像市场竞争对手分析

临床前成像市场是一个适度整合的市场，参与者有大有小。 一些市场参与者是 Aspect Imaging Corporation、Bruker Corporation、Fujifilm Holdings Corporation、Li-Cor Biosciences、Mediso Ltd、Milabs BV、MR Solutions Ltd、PerkinElmer Corporation、Euro Bioimaging Eric、Trifoil Imaging、United Imaging Healthcare、Photon 等，AXT PTY LTD、Advanced Molecular Vision, Inc、IVIM Technology Corp.等 玩家正在采取各种策略，例如新产品发布和收购，以保持竞争力。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 分子成像技术进步
    • 对非侵入性小动物成像技术的需求不断增加
    • 私人和公共机构对临床前研究的资助增加
  • 市场製约因素
    • 临床前研究的严格规定
    • 与临床前成像模式相关的高昂引进和运营成本
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按方式
    • 光学成像设备
    • 核医学成像系统
    • 显微核磁共振成像
    • 微超声
    • 显微CT
    • 光声成像装置
    • 其他方式
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Aspect Imaging Ltd
    • Bruker Corporation
    • Fujifilm Holdings Corporation
    • Mediso Ltd
    • MR Solutions Ltd
    • PerkinElmer Inc.
    • Trifoil Imaging
    • Euro-BioImaging ERIC
    • United Imaging Healthcare Co. Ltd
    • Photon etc.
    • AXT PTY LTD
    • Advanced Molecular Vision, Inc.
    • IVIM Technology Corp.

第7章 市场机会与今后动向

简介目录
Product Code: 47303

The preclinical imaging market is expected to register a CAGR of nearly 6.00% during the forecast period (2022-2027).

The current coronavirus disease 2019 (COVID-19) crisis has worsened, and clinical operations have changed dramatically. According to the article "The Current Coronavirus Disease 2019 (COVID-19) Crisis Continues to Grow and Has Resulted in Marked changes to clinical operations," published in 2020, academic medical centers and universities have rushed to shut down scientific research activities to maximize social distancing and minimize the spread of infection to research staff and others with whom they might come into contact, in parallel with clinical preparedness. Researchers in the field of radiology were wrestling with these issues, which will continue to affect present and future imaging studies.

However, with travel restrictions and improved sanitary precautions in place, Several manufacturers have resumed operations. Euro-BioImaging Nodes, for example, are tailored to the COVID-19 setting to give services to external users. Furthermore, Euro-BioImaging is assisting COVID-19-related research efforts, such as major drug screening projects, with picture data exchange. The company is collaborating with EU-OPENSCREEN, a partner research infrastructure. Using human cells and a SARS-CoV-2 isolate, EU-OPENSCREEN tested 5,632 chemicals for their ability to suppress viral-induced cytotoxicity to identify potential candidates for clinical trials against SARS-CoV-2. This is expected to boost the demand for preclinical imaging during the COVID-19 pandemic.

Also, in March 2020, MILabs improved their preclinical diagnostic U-CT system for in-vivo imaging of COVID-19 animal models in anticipation of rising demand for antiviral research tools and to enable the testing of coronavirus vaccines and medications. Ultra-high-resolution non-invasive lung imaging is one of the new features, allowing researchers to pinpoint the exact location of diseased processes in the bronchi of mice, guinea pigs, and ferrets. Furthermore, employing intrinsic freeze-frame lung imaging, up to four mice models can be scanned simultaneously for high-throughput screening of respiratory syndrome-associated coronavirus genotypes.

The major factors leading to the growth of the preclinical imaging market include the technological advancements in molecular imaging, increasing demand for non-invasive small animal imaging techniques, and an increase in preclinical research funding, by both private and public organizations.

Molecular imaging is a rapidly developing multidiscipline, which involves molecular biology, chemistry, computer, engineering, and medicine. It can recognize non-invasive and real-time visualization and measurement of the physiological or pathological process in the living organism at the cellular or molecular level.

Multimodal molecular imaging can play important role in the clinical care of various diseases by improving clinicians' ability to perform screening, surveillance, staging, prognosis, planning and therapy guidance, monitoring therapy efficacy, and assessing recurrence.

With its rapid technological advances, presymptomatic detection, targeted therapy, and personalized medicine may be possible shortly through the use of multimodal molecular imaging. Aspect imaging developed Aspect's M2 platform and the suite of products enable researchers to harness the power and quantitative insights of MRI for small animal phenotyping and drug development but without the cost, complexity, and technical burden of traditional MRI systems.

Preclinical Imaging Market Trends

Micro-Ultrasound is the Segment by Modality and is Expected to be the Fastest Growing Market

Micro-ultrasound is a miniature version of ultrasound that has a wider range of applications, especially in research related to small animal models. These smaller versions of imaging techniques boost the efficacy of the techniques. As per the study published in May 2020 titled 'Preclinical Ultrasound Imaging-A Review of Techniques and Imaging Applications', ultrasound imaging is a well-established clinical imaging technique providing real-time, quantitative anatomical and physiological information in humans.

Additionally, they reduce the number of animals required for a particular study. Over the past decade, preclinical imaging has emerged as an important tool to facilitate biomedical discovery. The high-frequency micro-ultrasound steadily evolved in the post-genomic era as a rapid, comparatively inexpensive imaging tool for studying normal development, and models of human disease in small animals. One of the fundamental barriers to this development was the technological hurdle associated with high-frequency array transducers.

Product launches are another factor in the growth of the market. For instance, in October 2020, Fox Chase Cancer Center has unveiled a new micro-ultrasound system that physicians say could change the way prostate cancer is diagnosed and treated. Such approvals are expected to boost market growth.

The applications of preclinical micro-ultrasound are explored for developmental biology, cancer, and cardiovascular disease. Concerning the future, the latest developments in high-frequency ultrasound imaging are also being developed. The combination of multiple imaging modalities in preclinical studies will help the researchers to understand the molecular, cellular, and physiological changes in living animals and to predict the outcome of new treatments in patients. Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.

North America is Expected to Dominate the Preclinical Imaging Market

North America is expected to dominate the preclinical imaging market because the region has a developed infrastructure, a large number of preclinical projects, and higher adoption rates of technically advanced devices in the region.

The COVID-19 pandemic and its aftermath have had a significant impact on academic studies in the United States. Coronavirus disease 2019 (COVID-19) has ravaged the globe, killing hundreds of millions of people, shutting down economies, closing borders, and spreading misery on a global scale. Most non-COVID clinical research has been halted due to distance and transmission concerns. There were no licensed medicines or vaccinations available when SARS-CoV-2 appeared at the end of 2019. The present paradigm of traditional drug research and development, which takes years from start to finish, is being challenged by the urgent need for countermeasures during this crisis. Antivirals, immunomodulators, anticoagulants, and other medicines have accelerated pathways that can be used as "roadmaps" to help prioritize compounds for clinical testing.

Hence, The National Institutes of Health (NIH) announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership in April 2020, to establish a coordinated research strategy for prioritizing and speeding the development of the most promising treatments and vaccines.

The United States is also found to be dominating the market, owing to the presence of established infrastructure and the presence of major public and private companies. The increased research and development funding that is taking place, coupled with the presence of a highly developed research infrastructure, is accelerating the growth of the preclinical imaging market in the United States.

Furthermore, the increasing number of clinical research organizations (CROs) and pharmaceutical companies are thereby increasing the adoption of in-vivo imaging systems in Preclinical research, which is further accelerating the growth of this market.

In addition, corporations are offering new products to diversify their product portfolio. Bruker, for example, announced the debut of the Ultima Investigator Plus in March 2022, the newest modular platform addition to the industry-leading Ultima range of multiphoton microscopes for deep tissue fluorescence imaging. Investigator Plus enhances scientists' capacity to image deep and see more within tough specimens with an extended field of view, optimized optics for two- and three-photon imaging, and an increased close-coupled collection path. In addition, organizations are advancing on new products to expand their product portfolio. Bruker, for example, revealed the unveiling of the Ultima Investigator Plus in March 2022, the newest flexible platform addition to the industry-ahead Ultima range of multiphoton microscopes for deep tissue fluorescence imaging. Researcher enhances scientists' ability to image deep and see more within specimens with an extended field of view, optimized optics for two and three-photon imaging, and an expanded close-coupled collection path.

Thus, all these factors have contributed to the growth of the market in the region.

Preclinical Imaging Market Competitor Analysis

The market studied is a moderately consolidated market owing to the various small and large market players. Some of the market players are Aspect Imaging Ltd, Bruker Corporation, Fujifilm Holdings Corporation, Li-Cor Biosciences, Mediso Ltd, Milabs BV, MR Solutions Ltd, PerkinElmer Inc., Euro-BioImaging ERIC, Trifoil Imaging, United Imaging Healthcare Co., Ltd., Photon etc., AXT PTY LTD, Advanced Molecular Vision, Inc., and IVIM Technology Corp. The players are adopting various strategies such as new product launches, and acquisition to remain competitive.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Molecular Imaging
    • 4.2.2 Increasing Demand for Non-invasive Small Animal Imaging Techniques
    • 4.2.3 Increase in Preclinical Research Funding, by Both Private and Public Organizations
  • 4.3 Market Restraints
    • 4.3.1 Strict Regulations in Preclinical Research
    • 4.3.2 High Installation and Operational Costs associated with Preclinical Imaging Modalities
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Modality
    • 5.1.1 Optical Imaging Systems
    • 5.1.2 Nuclear Imaging Systems
    • 5.1.3 Micro-MRI
    • 5.1.4 Micro-ultrasound
    • 5.1.5 Micro-CT
    • 5.1.6 Photoacoustic Imaging Systems
    • 5.1.7 Other Modality
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aspect Imaging Ltd
    • 6.1.2 Bruker Corporation
    • 6.1.3 Fujifilm Holdings Corporation
    • 6.1.4 Mediso Ltd
    • 6.1.5 MR Solutions Ltd
    • 6.1.6 PerkinElmer Inc.
    • 6.1.7 Trifoil Imaging
    • 6.1.8 Euro-BioImaging ERIC
    • 6.1.9 United Imaging Healthcare Co. Ltd
    • 6.1.10 Photon etc.
    • 6.1.11 AXT PTY LTD
    • 6.1.12 Advanced Molecular Vision, Inc.
    • 6.1.13 IVIM Technology Corp.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS